Curriculum vitae of MARCO RINALDO OGGIONI, born in Legnano (Italy) on January 1st 1965. Italian and German citizen.
CONTACT
Dip di Farmacia e Biotecnologie, University of Bologna, Via Irnerio 42, 40126 Bologna, IT marcorinaldo.oggioni@unibo.it [mailto:marcorinaldo.oggioni@unibo.it]
POSITION
2020- Professor of Microbial Genetics, Dip. Farmacia e Biotecnologie FaBiT, Università di Bologna, Bologna, Italy.
2025- Emeritus Professor, Dept of Genetics and Genome Biology, University of Leicester, Leicester, UK.
PREVIOUS POSITIONS
2015-2020 Honorary Consultant Microbiologist, University Hospitals of Leicester NHS Trust, Leicester, UK.
2013-2025 Professor, Dept of Genetics and Genome Biology, University of Leicester, Leicester, UK.
1993-2013 Consultant Clinical Microbiologist, Siena University Hospital (Azienda Ospedaliera Univ. Senese), Siena, Italy
1993-2013 Professor of Microbiology (non-tenure) at the Medical School, University of Siena, Siena, Italy.
EDUCATION/SERVICES
2023- Registration with the Medical Council of Bologna (Ordine dei Medici)
2022- Steering group Italian Society of General Microbiology SIMGBM
2019- Fellow of the International Society of Antimicrobial Chemotherapy FISAC
2015-18 Chair of the ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)
2015- Fellow of the UK Higher Education Academy FHEA
1994 Specialisation Degree in Microbiology and Virology, University of Siena, Italy
1990 Medical Degree, Medical School of the University of Verona, Italy
GRANTS (current)
IT
2025-26 Human Technopole grant 25-G-ROUND-1, 2068360. Spatial sequencing of perfused spleens. PI
2024-28 EU grant GAP–101186900 BactEradiX. Coll.
2024-26 GSK Contract Research In vivo models for pathogen research. PI.
2024-27 EU grant GAP-101131231 AMRAMR. PI
2023-25 PRIN PNRR grant P2022M8KYE. The innate immune reaction to invasive infection in human organs. PI.
2023-26 Cystic Fibrosis Foundation FFC grant FFC#13/2023. Aptides for the prevention of Pseudomonas infections. CoI.
2023-26 Ricerca Finalizzata RF-2021-12375437. RNA vaccine for S. pneumoniae and MTB. CoI.
2022-25 EU grant PNRR PE13 INF-ACT PE00000007. Emerging Infectious Diseases. CoI
2022-25 PRIN 2020 grant 202089LLEH. The CoDiCo (colonisation to disease concepts) project. PI.
2022-23 Fondazione del Monte. 1360bis/2021. Migratory birds and risk of viral spillover. CoI.
UK
2022-27 BRC NIHR203327. Leicester NIHR Biomedical Research Centre. CoI.
2022-25 BHF Project Grant PG/22/11117. Epigenetic phase variation of periodontal bacteria. CoI.
CLINICAL TRIALS:
2023-26 MOISE, CE-AVEC:668/2023/Sper/AOUBo of 19/10/2023. End date 18/10/2026. Scientific responsible.
2021-25 TIMOLD, ClinicalTrials.gov NCT05255042, REC: 21/PR/0287, IRAS 293486. End date: 31/12/2025. Chief Invest.
2018-25 TIMID, ClinicalTrials.gov NCT04620824, REC 18/EM/0057, IRAS 219992, End date: 31/12/2025. Chief Invest.
2019-21 Pollution and Health (PHN), REC 19/NW/0584, IRAS 264311, End date: 31/08/2021. Chief Invest.
PATENTS:
2009 Antigenic protein fragments of Streptococcus pneumoniae, International patent WO/2009/115509.
RESEARCH INTERESTS: Analysis of the molecular basis of mechanisms involved in the interaction of bacterial pathogens with their environment - the human host - by use of genomic tools and the study of microbial physiology. Most recent contributions were the identification of phase variable epigenetic control in bacteria and bacterial replication within a subset of tissue macrophages prior to invasive disease. Additional interests include investigation into the molecular determinants of antimicrobial drug resistance and mechanisms governing mobile genetic elements.
PUBLICATIONS (orcid.org/0000-0003-4117-793X)
publications: 156
h index:61
